Quarterly report pursuant to Section 13 or 15(d)

Sublicensing and Collaborative Agreements (Details Narrative)

v3.21.2
Sublicensing and Collaborative Agreements (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Aug. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Performance obligations   $ 3,556,400  
Upfront license payment $ 5,000,000.0    
Devlopment and commercelization $ 172,000,000.0    
Revenue   354,100 $ 0
AffaMed Agreement [Member]      
Revenue   $ 354,100 $ 0